Slovenia’s Novartis opens new EUR 40 million facility

Novartis in Slovenia officially opened its new viral vector production facility (VIFA One) in Menges. The opening event was attended by the Minister of Higher Education, Science, and Innovation of the Republic of Slovenia, Igor Papic, PhD, as the keynote speaker. With this EUR 40 million investment, Novartis significantly expands its research and production capabilities in the biopharmaceutical sector and strengthens Slovenia´s key role within one of the world´s leading pharmaceutical companies.

The specialized VIFA One facility will support the production of viral vectors for breakthrough cell and gene therapies for the treatment of certain autoimmune and genetic diseases and cancers. The fully automated production environment will ensure precision and efficiency at all stages of the production process under one roof, using advanced robotics.